Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-01-07

Clinical Trial Update: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adjunctive Troriluzole for obsessive-compulsive disorder has completed, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Troriluzole (troriluzole)

Snippet

Sponsor: Biohaven Pharmaceuticals, Inc. | Conditions: Obsessive-Compulsive Disorder | Phase 3 | Status: COMPLETED